Medical Disclaimer: This site provides informational comparisons only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult your physician or pharmacist before making medication decisions.

DrugNote

LERODALCIBEP-LIGA

Other

Brand names: LEROCHOL

Subcutaneous

Mechanism of Action

12.1 Mechanism of Action Lerodalcibep-liga is a recombinant fusion protein that binds PCSK9 with picomolar affinity. PCSK9 binds to low-density lipoprotein receptor (LDLR) on the surface of hepatocytes to promote LDLR degradation within the liver. By inhibiting the binding of PCSK9 to LDLR, lerodalcibep-liga increases the number of LDLRs available to clear LDL-C from the blood, thereby lowering LDL-C levels. [see Clinical Pharmacology ( 12.3 )] .

Indications

1 INDICATIONS AND USAGE LEROCHOL TM is indicated as an adjunct to diet and exercise to reduce low-density lipoprotein cholesterol (LDL-C) in adults with hypercholesterolemia
including heterozygous familial hypercholesterolemia (HeFH). ( 1 )

Contraindications

  • • 4 CONTRAINDICATIONS None. None. ( 4 )

Known Side Effects

0 documented side effects by frequency

No structured side effect data available.

Community Discussions

No community discussions found for LERODALCIBEP-LIGA yet.

Compare With

0 available comparisons

No comparisons yet.

Formulations

Dosage Forms

Tablet

Route

Subcutaneous